This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q81.1 / Special Copayment Reduction: V184 / Re-approval cycle: 5 years |
| B. Synonyms | Herlitz syndrome |
| C. Adult onset | Congenital onset; severe form fatal in the neonatal period to infancy; mild form (non-Herlitz type) can survive to adulthood |
| 1. History | First described by Herlitz in 1935; laminin-332 mutations identified in the 1990s |
| 2. Causes | Laminin-332 deficiency due to LAMA3, LAMB3, LAMC2 gene mutations → fragility of the dermal-epidermal junction |
| 3. Genetics | Autosomal recessive; biallelic mutations in one of LAMA3 (18q11.2), LAMB3 (1q32.2), LAMC2 (1q25.3) |
| 4. General epidemiology | Overall incidence of epidermolysis bullosa about 1/50,000; of these, the junctional type about 5~10% |
| 5. Pathophysiology | Laminin-332 deficiency → failure of hemidesmosome anchoring → separation of epidermis from basement membrane → blister formation with minor trauma |
| 6. Symptoms | Skin blisters and erosions at birth, involvement of oral, esophageal, and airway mucosa, growth impairment, recurrent infections |
| 7. Signs | Tense blisters, positive Nikolsky sign, erosions and crusts, oral mucosal erosions, failure to thrive, nail abnormalities |
| 8. Screening | Prenatal genetic testing (CVS/amniocentesis), immunofluorescence immunohistochemical mapping (immunomapping) |
| 9. Diagnosis | Skin biopsy TEM + immunofluorescence mapping + LAMA3/LAMB3/LAMC2 molecular genetic testing |
| 10. Treatment | Wound care, nutritional support, infection prevention, gene therapy clinical trials; no established curative therapy |
| 11. Prognosis | Herlitz type almost always fatal within infancy; non-Herlitz type can survive to adulthood but with high morbidity |
| 12. Prevention | Genetic counseling, prenatal molecular genetic diagnosis, preimplantation genetic diagnosis (PGD) |
| 13. References | Fine JD et al. (2014) Inherited epidermolysis bullosa: updated recommendations and 9 other papers |
Epidermolysis bullosa letalis (EB letalis) is one of the major subtypes of epidermolysis bullosa (EB) and the most severe subtype of junctional EB. The most widely known synonym for this disease, Herlitz syndrome, derives from the Swedish pediatrician Karl Herlitz, who in 1935 first described this disease with a fatal course as an independent clinical entity. Herlitz reported an unusual skin disease in which generalized blisters and erosions were observed in newborns who died within a few days after birth, and distinguished it from the previously known EB simplex.
In the mid-20th century, as classification systems for the various subtypes of epidermolysis bullosa developed, the concept of dividing them by site of blister formation into intraepidermal, junctional (dermal-epidermal junction), and subepidermal/dermolytic types became established. In particular, advances in electron microscopy in the 1960s~70s made it possible to determine the site of blister formation at the ultrastructural level, and it was shown that in epidermolysis bullosa letalis, separation occurs at the level of the lamina lucida.
The molecular pathogenesis was elucidated in the 1990s. In 1991, Verrando et al. and subsequently several research groups confirmed through immunofluorescence studies that deficiency of laminin-5 (now laminin-332), a key component of the basement membrane, is a characteristic finding of Herlitz junctional EB. Then, in the mid-1990s, research groups including Aberdam, Uitto, and McGrath confirmed that mutations in the LAMA3, LAMB3, and LAMC2 genes are the cause of this disease, establishing the molecular genetic basis.
Subsequently, large cohort studies were conducted through the efforts of the International EB Registry and expert groups, and the current standard diagnostic and classification guidelines were established through repeated revisions of the EB classification system led by Fine et al. (1994, 2008, 2014). Since the 2000s, research on gene therapy and stem cell therapy has been actively conducted, and promising results have been reported in some clinical trials. In particular, in 2023 the first EB gene therapy (Vyjuvek, beremagene geperpavec) received US FDA approval, beginning a shift in the treatment paradigm.
The cause of epidermolysis bullosa letalis is mutations in the genes encoding the component chains of laminin-332 (former names: laminin-5, kalinin/nisin/epiligrin), a key structural protein of the basement membrane at the dermal-epidermal junction. Laminin-332 is a heterotrimer protein composed of α3, β3, and γ2 chains, encoded by the LAMA3, LAMB3, and LAMC2 genes, respectively.
Laminin-332 is located at the boundary between the lamina lucida and the lamina densa of the basement membrane and acts as an anchor that fixes the hemidesmosome structures at the base of keratinocytes to the basement membrane. Specifically, laminin-332 binds α6β4 integrin and BP180 (BPAG2/collagen XVII) to form the hemidesmosome-basement membrane connection, and on the other side connects to dermal collagen structures through laminin-311, nidogen, etc.
In Herlitz EB, truncating mutations (nonsense, frameshift, splice-site variants) that abolish protein expression itself are mainly present on both alleles, so no laminin-332 is produced at all. In contrast, in non-Herlitz JEB, missense mutations that allow partial function are observed, so some laminin-332 is produced.
Of the three causative genes, LAMB3 mutations are the most common (about 60~70% of all JEB patients), and in particular the R635X (p.Arg635*) mutation is a hotspot mutation observed repeatedly in many populations. LAMA3 and LAMC2 mutations are relatively less common. Very rarely, JEB subtypes due to type XVII collagen deficiency (COL17A1 mutations) or α6β4 integrin deficiency (ITGA6, ITGB4 mutations) also exist, but these are classified as separate diseases.
Epidermolysis bullosa letalis follows an autosomal recessive mode of inheritance. The chromosomal locations of the three causative genes are as follows: LAMA3 (18q11.2), LAMB3 (1q32.2), LAMC2 (1q25.3). LAMB3 and LAMC2 are located close together on chromosome 1 but are far enough apart to segregate independently.
Each gene has a complex structure. LAMA3 consists of 77 exons, LAMB3 of 23 exons, and LAMC2 of 23 exons. The types of reported pathogenic variants are diverse, including nonsense mutations, frameshift insertions/deletions, splice-site mutations, missense mutations, and large exon deletions. Per HGMD (Human Gene Mutation Database), hundreds or more pathogenic variants are listed for each gene.
Genotype-phenotype correlation is important. The Herlitz type appears when both alleles carry variants abolishing protein expression (truncating mutations), and if even one allele allows residual protein expression through a missense or splice variant, it presents as the non-Herlitz type (mild). Therefore, in compound heterozygous patients, the phenotype is determined by the combination of the two variants.
The recurrence risk within the family is 25%, and carrier parents have no clinical symptoms. Consanguineous marriage increases the risk of homozygous mutations. Certain frequent mutations such as LAMB3 R635X arise repeatedly and independently without a founder effect (recurrent de novo mutation), corresponding to a CpG dinucleotide mutation hotspot. Identification of the familial mutation is essential for prenatal or preimplantation genetic diagnosis.
The incidence of all epidermolysis bullosa is reported as about 1/17,000~1/50,000 births, and junctional EB (JEB) accounts for about 5~10% of all EB. Therefore, the incidence of epidermolysis bullosa letalis (Herlitz JEB) is estimated at about 1/200,000~1/500,000 births.
According to data from the US National EB Registry (NEBR), the prevalence of JEB in the United States is about 2/1,000,000 people, and the Herlitz type is the most severe subtype among them. Similar levels have been reported in Europe, and epidemiologic data are accumulating through pan-European EB registries.
The sex ratio is equal, and although there may be differences in frequency among certain ethnic groups or regions, it is distributed worldwide. The LAMB3 R635X mutation is especially frequent in patients of European descent, and the frequency of this mutation implies a carrier frequency of about 1/500~1/1000 in the general population.
It is a rare disease in Korea, and accurate prevalence data are lacking. The number of patients registered for Special Copayment Reduction can be determined through the rare disease registration system, but under-registration is estimated to be considerable. In Korea as well, with improving molecular genetic diagnostic capacity, accurate subtype classification and patient registration are on the rise.
The core of the pathophysiology of epidermolysis bullosa letalis is structural weakening of hemidesmosomes at the epidermal-basement membrane junction. Normally, basal keratinocytes of the epidermis are firmly attached to the lamina lucida of the basement membrane through hemidesmosomes. The hemidesmosome is a complex multiprotein structure in which, on the inner side, BP230 (desmoplakin-related) connects to keratin intermediate filaments, and the transmembrane proteins BP180 (collagen XVII) and α6β4 integrin connect to the basement membrane via laminin-332.
When laminin-332 is deficient or loses function, α6β4 integrin and BP180 cannot be normally anchored to the basement membrane, and the anchoring function of the hemidesmosome is lost. In this state, when mechanical stimuli such as mild friction or pressure are applied, the epidermis separates from the basement membrane at the level of the lamina lucida, forming a blister. This separation occurs within the lamina lucida (intralamina lucida) or at the lamina lucida-lamina densa boundary.
Blister contents are initially seropurulent and become purulent with secondary infection. Because the basement membrane structures at the blister base remain on the dermal side, re-epithelialization of the eroded surface is theoretically possible, but continuous re-blistering results in repeated wounds.
Mucosal involvement occurs by the same mechanism. Because the mucosal epithelia of the esophagus, trachea, bladder, conjunctiva, oral cavity, etc. also use the same hemidesmosome-laminin-332 axis, laminin-332 deficiency causes blisters and erosions throughout the mucosa. The prominent tracheal mucosal involvement and granulation tissue formation in the Herlitz type reflect an abnormal inflammatory response during repeated wound healing.
In the long term, repeated wounds, inflammation, and fibrosis cause stenosis at various anatomic sites, such as the oral cavity, esophagus, urethra, and conjunctiva, and systemic malnutrition, susceptibility to infection, etc. combine to worsen the clinical course.
The clinical symptoms of epidermolysis bullosa letalis appear at birth or shortly after birth, and the main symptoms are skin blisters and erosions occurring spontaneously or with minor trauma. In the Herlitz type, symptoms are very severe and extensive, involving both the entire skin and the mucosa.
Skin symptoms are characterized by tense or flaccid blisters that form easily with mild friction, extensive erosions after blister rupture, and the resulting crusting. They occur especially at pressure sites (ears, heels, back, etc.), the diaper area, and sites of friction with clothing.
Involvement of the oral and gastrointestinal mucosa is an important feature of the Herlitz type; oral blisters and erosions cause painful stomatitis and difficulty nursing and feeding. Esophageal involvement causes dysphagia, esophageal stricture, and gastroesophageal reflux. In severe cases, placement of a gastrostomy tube is needed. Failure to thrive and malnutrition are important clinical problems of the Herlitz type.
Airway mucosal involvement is also characteristic. Hoarseness, airway stenosis, and dyspnea due to blisters and erosions of the subglottic and tracheal mucosa may occur, and these are life-threatening complications. In the Herlitz type, laryngotracheal stenosis is one of the main causes of death. Recurrent skin and mucosal infections, especially staphylococcal infections, are common, and the risk of bacteremia and sepsis is high. Metabolic abnormalities such as anemia and hypoalbuminemia are also present.
The most prominent sign on physical examination is tense blisters and extensive erosions throughout the skin. The blisters have relatively well-defined borders, and the Nikolsky sign, lateral extension on pressure, is positive. The skin around the blisters peels easily and has reduced elasticity.
After blister rupture, the eroded surfaces are exudative and easily become secondarily infected, forming purulent exudate and thick crusts. After healing, scar formation may be minimal or absent (a difference from the simplex type), but atrophic scars may form due to repeated inflammation.
In the oral cavity, mucosal blisters, erosions, tongue adhesion (tongue tie, ankyloglossia), enamel hypoplasia, restricted mouth opening, etc. are observed. Formation of granulation tissue in surrounding tissues is particularly characteristic of the Herlitz type; this results from abnormal repeated wound healing and is prominent around the nose, lips, neck, upper limbs, etc.
Systemic signs such as nail dystrophy or complete absence of nails (anonychia), failure to thrive, frailty, and anemia are also observed. Ophthalmologically, conjunctivitis, corneal erosions, and symblepharon may appear. Early dental caries and tooth loss due to enamel dysplasia are also common findings.
For screening for epidermolysis bullosa letalis, family history-based prenatal diagnosis is most important. In parents who have had an affected child or couples identified as carriers, prenatal diagnosis is recommended in each subsequent pregnancy.
Prenatal ultrasound may give limited suggestion of fetal skin abnormalities when skin involvement is severe, but its sensitivity and specificity are very low, so it cannot be used as a means of confirmation. Skin thickening, finger adhesions, etc. are sometimes suggested on ultrasound, but this is rare.
Immunofluorescence immunomapping (IF immunomapping) is a diagnostic method performed on skin biopsy tissue that uses antibodies to basement membrane components such as laminin-332, collagen XVII, and integrin α6β4 to identify reduced or absent expression. In the Herlitz type, marked reduction or absence of laminin-332 expression is observed. This is useful for phenotype confirmation and classification before molecular genetic testing.
When there is a family history, molecular genetic testing of the LAMA3, LAMB3, and LAMC2 genes is performed through chorionic villus sampling (CVS) or amniocentesis. Targeted mutation analysis is used when the causative familial mutation is known, and NGS panel testing when it is not. Preimplantation genetic diagnosis (PGD) can also be offered as an option.
The standard for confirming epidermolysis bullosa letalis is a three-part approach of clinical findings + skin biopsy + molecular genetic testing. The international EB diagnosis and classification guideline published by Fine et al. in 2014 is currently used as the clinical standard.
Transmission electron microscopy (TEM) of skin biopsy confirms that the site of blister formation is within the lamina lucida or at the lamina lucida-lamina densa boundary. Structural abnormalities of hemidesmosomes (hypoplasia, irregular shape) and cell separation within the lamina lucida are characteristic. TEM is the most important morphologic method for subtype classification of epidermolysis bullosa.
Immunofluorescence mapping applies various basement membrane protein antibodies (anti-laminin-332, anti-collagen XVII, anti-integrin α6β4, etc.) to frozen sections to evaluate the presence and location of each protein. In Herlitz JEB, laminin-332 immunofluorescence is markedly reduced or absent, and it also helps identify the site of separation.
For molecular genetic testing, EB gene panel NGS testing including LAMA3, LAMB3, and LAMC2 is performed as standard. Molecular confirmation is made when pathogenic variants are identified on both alleles. Phenotype-genotype correlation analysis is performed in combination with clinical findings and immunomapping. When there is a family history, the familial variants are identified first to optimize testing of the index patient.
There is to date no curative therapy for epidermolysis bullosa letalis, and treatment centers on supportive care of wound care, nutritional support, and prevention and treatment of complications. A multidisciplinary approach is essential, with collaboration among dermatology, neonatology, pediatrics, gastroenterology, otolaryngology, ophthalmology, nutrition, rehabilitation medicine, etc.
Wound care is the core of treatment, treating blisters and erosions with soft non-adherent wound dressings. In principle, blisters are punctured under aseptic conditions to drain their contents, without removing the roof. Specialized EB dressing products such as Mepilex Lite and Mepitel are used. The use of tape or adhesive dressings is prohibited. Administration of analgesics or premedication sedatives for pain management during dressing changes is needed.
Nutritional support is essential to overcome feeding difficulties due to esophageal involvement and pain. A high-calorie, high-protein diet and, when needed, placement of a nasogastric tube (NGT) or gastrostomy tube (PEG/PEJ) are required. Supplementation of micronutrients such as iron, zinc, vitamin D, and vitamin C is also important.
For infection control, topical antimicrobial care (mupirocin, chlorhexidine washes, etc.) is performed to minimize skin colonization by Staphylococcus aureus, Pseudomonas aeruginosa, etc. When bacteremia or sepsis occurs, aggressive systemic antibiotic treatment is needed.
Research on gene therapy has recently been active. Beremagene geperpavec (Vyjuvek), approved by the US FDA in 2023, is a herpes simplex virus (HSV)-based topical gene therapy carrying the COL7A1 gene; its indication is currently limited to dystrophic EB, but research on similar approaches for JEB is also underway. Clinical trials of cell therapies such as bone marrow transplantation and stem cell transplantation are also being conducted at some centers.
The prognosis of Herlitz epidermolysis bullosa letalis is very poor. According to NEBR data, about 40% of patients with the Herlitz type die within the first year of life, and most die in early infancy. Few patients survive beyond 2 years of age, and survival beyond childhood is very rare. The causes of death are mainly sepsis, pneumonia (aspiration or infectious), respiratory failure due to airway stenosis, malnutrition, multiorgan failure, etc.
The prognosis of patients with the non-Herlitz type (non-Herlitz JEB) is relatively good, and survival into adulthood is possible, but morbidity remains high. Generalized blister formation, recurrent infections, esophageal and airway stenosis, failure to thrive, chronic anemia, osteoporosis, etc. remain as long-term complications.
The psychosocial burden is also great; extreme pain, long dressing times, disfigurement, and restrictions on school and social activities markedly reduce the quality of life of patients and families. A palliative care approach should also be given important consideration in severe patients such as those with the Herlitz type. Recent advances in research on new treatments such as gene therapy are expected to contribute to improving future prognosis.
The key to prevention of epidermolysis bullosa letalis is genetic counseling and prenatal/preimplantation genetic diagnosis. Comprehensive counseling by a genetics specialist is needed for couples who have had an affected child or couples identified as LAMA3/LAMB3/LAMC2 carriers. It is made clear that there is a 25% risk of an affected child in each pregnancy, and options for prenatal diagnosis are provided.
Prenatal molecular genetic diagnosis is performed by CVS in the first trimester or amniocentesis in the second trimester, on the premise that the causative familial mutation has been identified. When prenatal diagnosis identifies an affected fetus, the decision whether to continue the pregnancy should be made after sufficient counseling that respects the parents' values and cultural and religious backgrounds.
Preimplantation genetic diagnosis (PGD) is a method of selecting out affected embryos without termination of pregnancy and is carried out through in vitro fertilization. It is technically established and can be performed when the mutations of both parents are known. Sufficient prior counseling about limitations such as cost and success rate is needed.
Carrier screening of the general population is currently not performed. Recommendation to avoid consanguineous marriage is also applied as a general prevention principle. In patients already affected, minimizing blister formation through skin protection education (avoiding trauma, wearing appropriate clothing, appropriate dressing techniques) contributes to preventing complications.